Search

Search Results

• 

  Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

  Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

  29-12-2022

  https://doi.org/10.4081/dr.2023.9613

  1836

  PDF: 568

  HTML: 103
• 

  A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata

  Tueboon Sriphojanart, Saranya Khunkhet, Poonkiat Suchonwanit

  30-11-2017

  https://doi.org/10.4081/dr.2017.7399

  4791

  PDF: 930

  HTML: 393

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2870

  PDF: 1017

  HTML: 40

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  1139

  PDF: 658

  HTML: 52
• 

  Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

  Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

  21-11-2022

  https://doi.org/10.4081/dr.2022.9265

  1586

  PDF: 476

  HTML: 38
• 

  Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines

  Valeria Corazza, Francesco Cusano, Ornella De Pità, Luigi Rossi, G. Giovanni Virno

  28-12-2021

  https://doi.org/10.4081/dr.2022.9454

  4172

  PDF: 695

  APPENDIX: 198

  HTML: 22
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1835

  PDF: 705

  HTML: 92
• 

  Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease

  Klaudia Miklusiak, Karol Miklusiak, Olga Kaczmarczyk, Dorota Cibor, Małgorzata Zwolińska-Wcisło

  22-05-2023

  https://doi.org/10.4081/dr.2023.9630

  1126

  PDF: 595

  HTML: 98
• 

  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

  Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

  01-10-2018

  https://doi.org/10.4081/dr.2018.7859

  2145

  PDF: 1102

  HTML: 91
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1176

  PDF: 579

  HTML: 28

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1101

  PDF: 583

  SUPPLEMENTARY MATERIAL: 189

  HTML: 24

• Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

  Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

  06-12-2024

  https://doi.org/10.4081/dr.2024.10171

  1880

  PDF: 501

  HTML: 65

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  525

  PDF: 334

  HTML: 27

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1869

  PDF: 768

  HTML: 109

• Hidradenitis suppurativa: state-of-the-art review and update

  Marco Virone, Elena Zappia, Alberto Di Caro, Davide Carlesimo, Nicoletta Bernardini, Giovanni Pellacani, Antonio Giovanni Richetta, Steven Paul Nisticò, Annunziata Dattola

  27-08-2025

  https://doi.org/10.4081/dr.2025.10328

  1386

  PDF: 877

  HTML: 23
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1254

  PDF: 871

  HTML: 50

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  597

  PDF: 410

  HTML: 15
• 

  Erythrodermic psoriasis improved by tildrakizumab

  Giampaolo Trevisan, Lerica Germi, Luigi Naldi

  23-11-2022

  https://doi.org/10.4081/dr.2022.9448

  1377

  PDF: 644

  HTML: 29
• 

  Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

  Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

  29-07-2021

  https://doi.org/10.4081/dr.2021.8797

  3176

  PDF: 672

  HTML: 22

• New and emerging therapies in cutaneous T-cell lymphoma

  Gabriele Roccuzzo, Nicole Macagno, Silvia Giordano, Paolo Fava, Pietro Quaglino

  02-10-2024

  https://doi.org/10.4081/dr.2024.10002

  1235

  PDF: 700

  HTML: 110
• 

  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

  Catharina Margrethe Lerche, Hans Christian Wulf

  e13

  14-09-2010

  https://doi.org/10.4081/dr.2010.e13

  2236

  PDF: 891

  HTML: 182
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2673

  PDF: 661

  HTML: 16

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  642

  PDF: 332

  HTML: 26
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1993

  PDF: 760

  HTML: 55

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  905

  PDF: 477

  HTML: 54